Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (2) Cakmak-Görür, Nese Dr. (1) Daniel, Peter Prof. Dr. (2) Dhamodaran, Arunraj (1) Kammertöns, Thomas Dr. (5) Kopp, Joachim Dr. (2) Leisegang, Matthias Prof. Dr. rer. nat. (3) Lorenz, Felix Dr. (1) Pezzutto, Antonio Prof. Dr. (3) Poncette, Lucia (1) Rhein, Simone Dr. (1) Siffrin, Volker (1) Uckert, Wolfgang Prof. Dr. (4) Willimsky, Gerald Dr. (3) (-) Blankenstein, Thomas Prof. Dr. (14) (-) Marko, Lajos Dr. (1) AG Müller/Dechend (ECRC) (8) Bioinformatics and Omics Data Science (1) Biologie maligner Lymphome (11) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Hypertonie-vermittelter Endorganschaden (8) Hypertonie bedingte Endorganschäden (8) (-) Molekulare Immunologie und Gentherapie (15) Proteom Dynamik (1) Proteomics and Metabolomics (1) Strukturbiologie Membran-assoziierter Prozesse (1) Systembiologie von Gen-regulatorischen Elementen (1) Translational Bioinformatics (2) Wirt-Mikrobiom Faktoren in Herz-Kreislauferkrankungen (3) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) (-) 2015 (3) 2016 (4) 2017 (6) 2018 (4) (-) 2019 (7) 2021 (4) 2022 (6) 2023 (4) 2024 (2) 15 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Marko, Lajos Dr.Molekulare Immunologie und Gentherapie 201120152019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein 13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein 15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann 01. April 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber 01. April 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein 27. November 2019 / BMC Med Genomics Identification and ranking of recurrent neo-epitopes in cancer E. Blanc M. Holtgrewe A. Dhamodaran C. Messerschmidt G. Willimsky T. Blankenstein D. Beule 24. März 2019 / OncoImmunology Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer L. Penter K. Dietze J. Ritter M.F. Lammoglia Cobo J. Garmshausen F. Aigner L. Bullinger H. Hackstein S. Wienzek-Lischka T. Blankenstein M. Hummel K. Dornmair L. Hansmann Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein
15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann
01. April 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
01. April 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
27. November 2019 / BMC Med Genomics Identification and ranking of recurrent neo-epitopes in cancer E. Blanc M. Holtgrewe A. Dhamodaran C. Messerschmidt G. Willimsky T. Blankenstein D. Beule
24. März 2019 / OncoImmunology Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer L. Penter K. Dietze J. Ritter M.F. Lammoglia Cobo J. Garmshausen F. Aigner L. Bullinger H. Hackstein S. Wienzek-Lischka T. Blankenstein M. Hummel K. Dornmair L. Hansmann